Author

P. Halfon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 4 Research Focus:host-pathogen & immune response· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:rat· 2 Assay:bulk RNA-seq· 1 Organism:mouse· 1

Frequent Co-Authors

S. MEZOUAR· 6 shared E. Bestion· 4 shared B. La Scola· 3 shared J.-L. Mege· 3 shared T. Decaens· 3 shared C. Ansaldi· 2 shared D. Olive· 2 shared E. Raymond· 2 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

S. MEZOUAR

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Targeting PPT1 with ezurpimtrostat sensitives liver tumor to immunotherapy by switching cold into hot microenvironments

E. Bestion, M. Rachid, A. Tijeras-Raballand, G. Roth, T. Decaens, C. Ansaldi, S. MEZOUAR, E. Raymond, P. Halfon

This paper shows that inhibiting PPT1 with ezurpimtrostat enhances anti-PD-1 immunotherapy in liver cancer by converting cold to hot tumors.

bioRxiv · Jan 18, 2023 · PreprintCancer Biology

Vγ9Vδ2 T cells are potent inhibitors of SARS-CoV-2 replication and exert effector phenotypes in COVID-19 patients

L. Gay, M.-S. Rouviere, S. Mezouar, M. Richaud, L. Gorvel, E. Foucher, L. Madakamutil, B. La Scola, A. Menard, J. Allardet-Servent, P. Halfon, P. Frohna, C. Cano, J.-L. Mege, D. Olive

This paper investigates how SARS-CoV-2 affects Vγ9Vδ2 T cells in patients and shows that anti-BTN3A activation enhances their antiviral response.

bioRxiv · Apr 15, 2022 · PreprintImmunology

GNS561, a new autophagy inhibitor active against cancer stem cells in hepatocellular carcinoma and hepatic metastasis from colorectal cancer

S. Brun, J.-M. Pascussi, E. P. Gifu, E. Bestion, Z. Macek-Jilkova, G. Wang, F. Bassissi, S. Mezouar, J. Courcamberck, P. Merle, T. Decaens, J. Pannequin, P. Halfon, C. Caron de Fromentel

This study shows that GNS561, an autophagy inhibitor, effectively targets both cancer stem cells and bulk tumor cells in hepatocellular carcinoma and colorectal cancer metastasis.

bioRxiv · Dec 21, 2020Cancer Biology

GNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition

P. Halfon, E. Bestion, K. Zandi, J. Andreani, J.-P. Baudoin, B. LA SCOLA, J.-L. Mege, S. Mezouar, R. F. Schinazi

This study shows GNS561, an autophagy inhibitor, has strong antiviral effects against SARS-CoV-2, both alone and in combination with remdesivir.

bioRxiv · Oct 6, 2020Pathology

GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions

S. BRUN, E. Raymond, F. Bassissi, Z. M. Jilkova, S. Mezouar, M. Rachid, M. Novello, J. Tracz, A. Hamai, G. Lalmanach, L. Vanderlynden, E. Bestion, R. Legouffe, J. Stauber, T. Schubert, , P. Halfon

This paper evaluates GNS561, a PPT1 inhibitor, showing its efficacy against HCC by modulating lysosomal functions and inducing cell death in vitro and in vivo.

bioRxiv · Sep 30, 2020Cancer Biology

Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis

A. Boumaza, L. Gay, S. Mezouar, A. B. Diallo, M. Michel, B. Desnues, D. Raoult, B. LA SCOLA, P. Halfon, J. Vitte, D. Olive, J.-L. Mege

This study shows SARS-CoV-2 infects monocytes and macrophages, inducing immunoregulatory cytokine secretion and M2-type transcriptional changes, leading to immunoparalysis in Covid-19 patients.

bioRxiv · Sep 17, 2020Immunology